Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Shannon N. Westin; Marilyne Labrie; Jennifer K. Litton; Aurora Blucher; Yong Fang; Christopher P. Vellano; Joseph R. Marszalek; Ningping Feng; Xiaoyan Ma; Allison Creason; Bryan Fellman; Ying Yuan; Sanghoon Lee; Tae‐Beom Kim; Jinsong Liu; Anca Chelariu-Raicu; Tsun Hsuan Chen; Nashwa Kabil; Pamela T. Soliman; Michael Frumovitz; Katheleen M. Schmeler; Amir A. Jazaeri; Karen H. Lu; Rashmi K. Murthy; Larissa A. Meyer; Charlotte C. Sun; Anil K. Sood; Robert L. Coleman; Gordon B. Mills

doi:10.1158/1078-0432.ccr-21-1656

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

The combination of olaparib and capivasertib is associated to no serious adverse events and demonstrates durable activity in ovarian, endometrial, and breast cancers, with promising responses in endometrial cancer. Importantly, tumor samples acquired pre- and on-therapy can help predict patient benefit.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Westin et al. (2021) studied this question.

synapsesocial.com/papers/69dad7ca4a1e15904c836756 https://doi.org/10.1158/1078-0432.ccr-21-1656

View Full Paper

Ask AI

Bookmark

Share

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading